Mr. Joshua Bartch reports

MYDECINE REPORTS ITS SPECIAL MEETING RESULTS

Mydecine Innovations Group Inc. has released the results of voting at its special meeting of shareholders which was held on Tuesday, July 4, 2023, by conference call. There were 15 shareholders represented in person or by proxy at the meeting, holding 3,670,377 common shares, representing 14.72 per cent of the company's total issued and outstanding common shares as of the record date for the meeting.

The voting results for the meeting are set out herein.

Approval of the repricing of debenture and debenture warrants

The resolution to authorize and approve the repricing of the debenture and the debenture warrants was approved by a majority of votes cast by the disinterested shareholders who voted for the resolution present or represented by proxy at the meeting.

The repricing of the debenture and debenture warrants will be implemented at the discretion of the board of directors, should the board of directors believe that the adoption of the repricing of the debenture and debenture warrants is in the best interest of the company.

Voting results are set out in the attached table.

Approval of other matters

The resolution to transact such other business that may be brought properly before the meeting and any adjournment or postponement of the meeting. Voting results are set out in the attached table.

About Mydecine Innovations Group Inc.

Mydecine Innovations Group is a biotechnology company developing the next generation of innovative medications and therapies to address mental health disorders such as nicotine addiction and posttraumatic stress disorder (PTSD). The core strategy blends advanced technology with an elaborate infrastructure for drug discovery and development. Mydecine's dedicated multinational team constantly develops new paths for breakthrough treatment solutions in areas with considerable unmet needs. By collaborating with some of the world's leading specialists, the company aspires to responsibly speed up the development of breakthrough medications to provide patients with safer and more effective treatment solutions. At the same time, Mydecine's approach focuses on the next generation of psychedelic medicine by creating innovative compounds with unmatched therapeutic potential through its clinical trial efforts with world-class scientific and regulatory expertise. Founded in 2020, Mydecine is based out of Colorado, United States, with extended offices in Alberta, Canada, and Leiden, Netherlands.

We seek Safe Harbor.